The spectrum of cytomegalovirus infection and its management.
The spectrum of cytomegalovirus infection and its management.
复制标题
巨细胞病毒感染的谱及其管理。
DOI：
10.1093/jac/23.suppl_e.1
复制
发表时间：
1989
影响因子：
5.2
通讯作者：
D. Jeffries
中科院分区：
文献类型：
--
作者：
D. Jeffries
巨细胞病毒(CMV)引起的严重疾病几乎完全局限于先天性感染的婴儿，免疫功能受损。细胞免疫主要负责控制初次感染后的感染和重新激活后预防疾病。在接受主动免疫抑制的移植患者中，药物方案的选择对于确定播散性CMV感染和疾病的可能性非常重要，通过减少使用剂量来控制感染是可能的。为了减少免疫缺陷患者巨细胞病毒的发病率和死亡率，已经引入了许多策略。这些措施包括预防性使用特定的免疫球蛋白或阿昔洛韦，以及几种在体外被证明具有抗CMV活性的抗病毒药物的治疗性使用。更昔洛韦(DHPG)和磷甲酸酯(Foscarnet)在临床试验中显示出最有希望的前景，更昔洛韦现在已获准在英国用于治疗危及视力和生命的感染。
Serious disease due to cytomegalovirus (CMV) is almost totally confined to congenitally infected infants and the immunocompromised. Cell-mediated immunity is primarily responsible for the control of infection following primary infection and for prevention of disease after reactivation. In patients receiving active immunosuppression for transplantation, the choice of drug regimens is important in determining the likelihood of disseminated CMV infection and disease and it may be possible to control the infection by reducing the doses used. A number of strategies have been introduced in attempts to reduce the morbidity and mortality of CMV in the immunocompromised. These include prophylactic administration of specific immunoglobulin or acyclovir and the therapeutic use of several antiviral agents shown to have activity against CMV in vitro. Ganciclovir (DHPG) and foscarnet (phosphonoformate) have shown the most promise in clinical trials and ganciclovir has now been licensed for use in the UK, in sight- and life-threatening infections.